Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1513 • ACR Convergence 2020
Role of Platelet C4d in Thrombosis and Lupus Nephritis
Michelle Petri¹, Jessica Li², John Conklin³, Tyler O'Malley⁴, Jo-Anne Ligayon⁵, Leilani Wolover⁵ and Thierry Dervieux⁶, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³Exagen Inc., Vista, CA, ⁴Exagen, Inc, San Diego, CA, ⁵Exagen Diagnostics, San Diego, CA, ⁶Prometheus Biosciences, Inc. (former employee of Exagen Diagnostics), Irvine, CA
Background/Purpose: The SLE thrombosis risk equation contains three components: lupus anticoagulant (dRVVT), low C3 and C4d bound to platelets (platelet C4d). We examined the role…
Abstract Number: 1672 • ACR Convergence 2020
Renal Activity Index for Lupus Nephritis Distinguishes Active Renal Disease Among Childhood Systemic Lupus Erythematosus Patients
Najla Aljaberi¹, Arjun Mathur², Steffy Jose³, Theresa Hennard⁴, Angela Merritt¹, Qing Ma⁵, James Rose⁵, Rashmi Sahay⁶, Chunyan Liu⁶, Scott Wenderfer⁷ and Hermine I Brunner⁸, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ³Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Divison of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁶Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁷Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ⁸PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Renal involvement in childhood-onset systemic lupus erythematosus (cSLE) is a major cause of morbidity and mortality. Current tools to identify lupus nephritis (LN) fall…
Abstract Number: 1776 • ACR Convergence 2020
Safety and Beneficial Effects of Hydroxychloroquine on Pregnancy Outcomes in Women with Systemic Lupus Erythematosus
Isabell Haase¹, Matthias Schneider¹, Ralph Brinks¹ and Rebecca Fischer-Betz¹, ¹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: The use of hydroxychloroquine (HCQ) has long been established in Systemic Lupus Erythematosus(SLE) and especially as applicable drug during pregnancy. Recently, beneficial effects and…
Abstract Number: 1802 • ACR Convergence 2020
Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE?
Ileannette Robledo-Vega¹, John Scheinuk², Emmanuel Pardo², Ansley Pratt², Soham Mahato³, Andrew G. Chapple² and Myriam Guevara⁴, ¹Louisiana State University Health Sciences Center, New Orlenas, LA, ²Louisiana State University, New Orleans, LA, ³LSUHSC School of Public Health, New Orleans, LA, ⁴Lousiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: There are few predominant African American (AA) epidemiological studies in Cutaneous Lupus Erythematosus (CLE). The Gilliam classification divides CLE into lupus specific, acute cutaneous…
Abstract Number: 1819 • ACR Convergence 2020
Altered Brain Functional Connectivity in Systemic Lupus Erythematosus
Michelle Barraclough¹, Shane McKie², Benjamin Parker¹, Alan Jackson³, Rebecca Elliott⁴ and Ian Bruce⁵, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²FBMH Platform Sciences, Enabling Technologies & Infrastructure, The University of Manchester, Manchester, ³Wolfson Molecular Imaging Centre, Institute of imaging and bioinformatics, The University of Manchester, Manchester, ⁴Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) is very prevalent in SLE and significantly affects quality of life. Altered functional brain mechanisms are associated with CD in SLE.…
Abstract Number: 1835 • ACR Convergence 2020
Evaluation of Low Dose Glucocorticoid Effects on Infection Occurrence in Systemic Lupus Erythematosus Patients
Kazuya Abe¹, Nobuyuki Yajima², Yuichi Ishikawa³, Yasuhiko Kita⁴, Ken-ei Sada⁵, Ryusuke Yoshimi⁶, Yasuhiro Shimojima⁷, Shigeru Ohno⁸, Hiroshi Kajiyama⁹, Kunihiro Ichinose¹⁰, Shuzo Sato¹¹ and Michio Fujiwara¹², ¹Department of Rheumatology, Yokohama Rosai Hospital, Chiba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Yokohama Rosai Hospital, Tokyo, Japan, ⁴Department of Rheumatology, Yokohama Rosai Hospital, kanagawa, ⁵Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ⁸Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁹Department of Rheumatology and Applied Immunology Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan, ¹⁰Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹¹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ¹²Department of Rheumatology, Yokohama Rosai Hospital, Kanagawa, Japan
Background/Purpose: Infection is major cause of morbidity and mortality in systemic lupus erythematosus (SLE) patient. The past exploratory study suggested various infection risk in SLE…
Abstract Number: 1987 • ACR Convergence 2020
Predictors of Adverse Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus Transitioning to Adult Care
Nicole Bitencourt¹, Una Makris¹, Elizabeth Solow¹, Tracey Wright² and Bonnie Bermas³, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Plano, TX, ³UTSouthwestern.edu, Dallas, TX
Background/Purpose: The transition from pediatric to adult care is a vulnerable period and is linked to increased healthcare utilization and poor outcomes. We sought to…
Abstract Number: 0048 • ACR Convergence 2020
Determinants of Participation in Clinical Trials Among Patients with Lupus in the United States
Onengiya Harry¹, Carl Langefeld², Miranda Marion³, Trent Younts³, Lori Crosby⁴, Mara Vitolins³ and Avani Modi⁴, ¹Wake Forest School of Medicine, Clemmons, NC, ²Wake Forest School of Medicine, Winston Salem, NC, ³Wake Forest School of Medicine, Winston-Salem, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati
Background/Purpose: Patient and family participation in research is critical to improving health outcomes, and identifying factors that contribute to participation or lack of participation in…
Abstract Number: 0256 • ACR Convergence 2020
Patient Perspective of the Type 1 and 2 SLE Model: A Qualitative Study
Amanda Eudy¹, Amy Corneli², Kevin McKenna², Mithu Maheswaranathan¹, Bryce Reeve², David Pisetsky³ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: To better characterize the signs and symptoms of systemic lupus erythematosus (SLE) we have developed a conceptual model to characterize SLE activity into two dimensions: Type 1…
Abstract Number: 0273 • ACR Convergence 2020
Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia
Jennifer Rogers¹, Megan Clowse², Lisa Criscione-Schreiber³, Jayanth Doss⁴, Rebecca Sadun⁴, Kai Sun⁵ and Amanda Eudy⁴, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University Hospital, Durham
Background/Purpose: Patients with SLE have poor health related quality of life (HRQoL), however the differences in the predominant causes of decreased HRQoL across subgroups of…
Abstract Number: 0291 • ACR Convergence 2020
SLAMF7 and CD38 on NK Cells Represent Potential New Therapeutic Targets for Systemic Lupus Erythematosus
Morgane Humbel¹, Florence Bellanger², Craig Fenwick², Alice Horisberger², Camillo Ribi² and Denis Comte², ¹CHUV, Lausanne, Vaud, Switzerland, ²CHUV, Lausanne, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by the production of autoantibodies. For this reason, anti-B cell therapy seems to be…
Abstract Number: 0433 • ACR Convergence 2020
Racial Disparities and New SLE-Specific Predictors of Stroke and Ischemic Heart Disease in Patients with Lupus
Shivani Garg¹, Christie Bartels², Gaobin Bao³, Cristina Drenkard⁴ and S. Sam Lim³, ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ³Emory University, Atlanta, GA, ⁴Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA
Background/Purpose: In the US, cardiovascular disease (CVD) is the leading cause of disparities in life expectancy between black and white populations. We recently reported a…
Abstract Number: 0570 • ACR Convergence 2020
The Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus
Jennifer Ra¹, Jerik Leung², Elizabeth Baker² and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Saint Louis University, College for Public Health and Social Justice, St. Louis
Background/Purpose: The clinical variability of systemic lupus erythematosus (SLE) caused by the unpredictability of flares contributes to patients experiencing a diminished sense of social support.…
Abstract Number: 0837 • ACR Convergence 2020
Deletion of miR-223 Exacerbates Lupus Nephritis by Targeting S1pr1 in Faslpr/lpr Mice
Sumie Hiramatsu Asano¹, Tomoyuki Mukai², Yoshitaka Morita³ and Jun Wada⁴, ¹Kawasaki Medical School/Department of Rheumatology, Kurashiki city, Japan, ²Kawasaki Medical School, Kurashiki-shi, Okayama, Japan, ³Kawasaki Medical School/Department of Rheumatology, Kurashiki, Okayama, Japan, ⁴Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences., Okayama city, Japan
Background/Purpose: To identify new candidate genes regulated by micro RNAs (miRNAs) and involved in the pathogenesis of systemic lupus erythematosus (SLE), we integrated miRNA and…
Abstract Number: 0857 • ACR Convergence 2020
Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory
Michelle Petri¹, Jessica Li², Kelley Brady³, John Conklin⁴, Tyler O'Malley⁵ and Thierry Dervieux⁶, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³Exagen Diagnostics, San Diego, CA, ⁴Exagen Inc., Vista, CA, ⁵Exagen, Inc, San Diego, CA, ⁶Prometheus Biosciences, Inc. (former employee of Exagen Diagnostics), Irvine, CA
Background/Purpose: Therapeutic blood monitoring is not yet an accepted practice in rheumatology. Although hydroxychloroquine (HCQ) blood level monitoring has been utilized in limited pharmacokinetic studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].